A Prospective, Multicenter, Single-Arm, Phase ???, Exploratory Clinical Trial Evaluating the Efficacy and Safety of Distitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.
Latest Information Update: 15 Oct 2024
At a glance
- Drugs Disitamab vedotin (Primary) ; Tislelizumab (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- 11 Oct 2024 New trial record